Sustained Dilation of Schlemm’s Canal
Project Description:
ViscoCure’s mission is to prevent avoidable, irreversible blindness. Glaucoma describes progressive vision loss due predominantly to elevated pressure in the front of the eye. Glaucoma is a leading cause of blindness worldwide, projected to represent over 110 million individuals by 2040 with an estimated market valuation of 5.8 billion USD. Glaucoma is an incurable chronic disease, and treatments aim to reduce pressure in the eye in order to prevent vision loss. ViscoCure aims to provide efficacious, cost-effective treatment for glaucoma patients. Ultimately, ViscoCure addresses the shortcoming of competing procedures and reduces the reliance on strict compliance with eye drop medication, a key pitfall of glaucoma management. Our method effectively drops intraocular pressure in a method that preserves the natural anatomy of the eye, is cost effective, minimally invasive, and a longer-term treatment irrespective of eye pigmentation.
Project Photo:
Failure of the conventional outflow pathway for aqueous humor results in high intraocular pressure
